Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer

Open source

DOI: 10.1056/nejmoa1606774
Published: 2016-11-10
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1606774,
  title = {Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer},
  author = {Martin Reck and Delvys Rodríguez-Abreu and Andrew G. Robinson and Rina Hui and Tibor Csőszi and Andrea Fülöp and Maya Gottfried and Nir Peled and Ali Tafreshi and Sinead Cuffe and Mary O’Brien and Suman Rao and Katsuyuki Hotta and Melanie A. Leiby and Gregory M. Lubiniecki and Yue Shentu and Reshma Rangwala and Julie R. Brahmer},
  year = {2016},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa1606774},
  url = {https://doi.org/10.1056/nejmoa1606774}
}

RIS

TY  - JOUR
TI  - Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
AU  - Martin Reck
AU  - Delvys Rodríguez-Abreu
AU  - Andrew G. Robinson
AU  - Rina Hui
AU  - Tibor Csőszi
AU  - Andrea Fülöp
AU  - Maya Gottfried
AU  - Nir Peled
AU  - Ali Tafreshi
AU  - Sinead Cuffe
AU  - Mary O’Brien
AU  - Suman Rao
AU  - Katsuyuki Hotta
AU  - Melanie A. Leiby
AU  - Gregory M. Lubiniecki
AU  - Yue Shentu
AU  - Reshma Rangwala
AU  - Julie R. Brahmer
PY  - 2016
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa1606774
UR  - https://doi.org/10.1056/nejmoa1606774
ER  -

APA

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1606774

Source records

crossref · retrieved 2026-09-25T08:27:43.233Z